Abstracts tagged "prevention"

Abstract Number: 1815 • ACR Convergence 2022
Consistent Colchicine Use Is Associated with Decreased Major Adverse Cardiovascular Events in Patients with Gout and Established Cardiovascular Disease
Gary Ho¹, Michael Toprover², Daria Crittenden³, binita Shah⁴ and Michael Pillinger⁵, ¹New York University Grossman School of Medicine, VA New York Harbor Health Care System, Brooklyn, NY, ²Division of Rheumatology, New York University Grossman School of Medicine and Rheumatology Section, New York Harbor Health Care System, New York Campus of the U.S. Department of Veterans Affairs, New York, NY, ³CymaBay Therapeutics, New York University Grossman School of Medicine, Newark, CA, ⁴New York University Grossman School of Medicine, VA New York Harbor Health Care System, New York, NY, ⁵NYU Grossman School of Medicine, New York, NY
Background/Purpose: Patients with gout are more likely than those without to have traditional risk factors for cardiovascular (CV) disease. Furthermore, the chronic, low-level inflammation experienced…
Abstract Number: 0939 • ACR Convergence 2022
Pilot Study: A Novel Method for Cervical Health Monitoring in African American Women with Systemic Lupus Erythematosus (SLE) Using a Self- Sampling Brush to Assess Cervical HPV Infection and Cervical Cytology
J. Patricia Dhar¹, Heather Walline², Lamia Fathallah³, Susanna Szpunar⁴, Louis Saravolatz⁵, Gil Mor⁶ and Thomas Carey⁷, ¹Ascension St. John Hospital and Wayne State University School of Medicine, Bloomfield Hills, MI, ²University of Michigan, Ann Arbor, MI, ³Ascension St.John Hospital, Detroit, MI, ⁴Ascension St. John Hospital, Grosse Pointe Woods, MI, ⁵Ascension St John Hospital and Medical Center, Wayne State University School of Medicine (affiliate), Grosse Pointe Woods, MI, ⁶Wayne State University and C.S. Mott Center for Human Growth and Development., Detroit, MI, ⁷University of Michigan School of Medicine, Ann Arbor, MI
Background/Purpose: A health disparity exists for AA women with SLE who have increased morbidity & mortality from both cervical cancer & SLE. Current cervical cancer…
Abstract Number: 1932 • ACR Convergence 2022
Efficacy of the COVID-19 Vaccine in Pediatric Systemic Lupus Erythematosus Patients
Yi Shi¹, Catherine Park², Sangeeta Sule² and Sun-Young Ahn², ¹Children's National Hospital, New York, NY, ²Children's National Hospital, Washington, DC
Background/Purpose: The COVID-19 virus has caused significant morbidity and mortality, despite introduction of the COVID vaccine. Immunocompromised patients have been shown to have reduced response…
Abstract Number: 0945 • ACR Convergence 2022
Contraception Documentation Patterns for Adult Females with Juvenile Idiopathic Arthritis on Teratogenic Medications in the Rheumatology Informatics System for Effectiveness (RISE) Registry
John Bridges¹, Jing Li², Melissa Mannion³, Gabriela Schmajuk⁴ and Jasvinder singh³, ¹University of Alabama at Birmingham/Children's of Alabama, Birmingham, AL, ²University of California, San Francisco, San Francisco, CA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴UCSF / SFVA, San Francisco, CA
Background/Purpose: Patients with juvenile idiopathic arthritis (JIA) have disease onset during childhood and often require anti-rheumatic medication through their reproductive years. Contraception use in reproductive-age…
Abstract Number: 1964 • ACR Convergence 2022
Systematic Screening of Multimorbidities Results in an Increased Intake of Comorbidity Preventive Medications and a Decreased Hospitalization Rate
Claire DAIEN¹, Vera Georgescu², Guillaume Decarriere³, Jenica Pastor³, Gaël Mouterde⁴, Cédric Lukas⁵, Grégoire Mercier³ and Jacques Morel⁶, ¹University Hospital, Saint-Gély-du-Fesc, France, ²Unité de Recherche Médico-économique, CHU de Montpellier et Université de Montpellier, Montpellier, France, ³CHU Montpellier, Montpellier, France, ⁴Lapeyronie Hospital, Montpellier, France, ⁵University Hospital Centre Montpellier, University of Montpellier, Montpellier, France, ⁶University and CHU Montpellier, Montpellier, France
Background/Purpose: A systematic screening of multimorbidities is performed since 2014 at the Montpellier University Hospital in patients with chronic inflammatory rheumatic diseases (IRD). The objective…
Abstract Number: 0064 • ACR Convergence 2022
Utilization of Preventive Services in a Systemic Lupus Erythematosus Population-Based Cohort: A Lupus Midwest Network Study
Baptiste Chevet¹, Gabriel Figueroa Parra¹, Jeffrey X. Yang¹, Mehmet Hocaoglu¹, Shirley-Ann Osei-Onomah¹, Cassondra Hulshizer¹, Tina Gunderson¹, Divi CORNEC², Cynthia Crowson³ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²CHRU Brest, Brest, France, ³Mayo Clinic, Eyota, MN
Background/Purpose: Systemic lupus erythematosus (SLE) is a disease that can damage multiple organs and, along with certain treatments, increase the risk of developing cancer, cardiovascular…
Abstract Number: 0947 • ACR Convergence 2022
Development of a Person-Centered Family Planning Decision Aid for Women with Rheumatic Diseases
Mehret Birru Talabi¹, Traci Kazmerski², Raelynn O'Leary³, Ashley Deal³, Megan Clowse⁴, Oilvia Stransky⁵ and Sonya Borrero⁵, ¹University of Pittsburgh, Pittsburgh, PA, ²Children's Hospital of Pittsburgh, Pittsburgh, ³Carnegie Mellon University School of Design, Pittsburgh, ⁴Duke University, Durham, NC, ⁵University of Pittsburgh, Pittsburgh
Background/Purpose: Given the potential for pregnancy-associated mortality and morbidity, the question of whether and/or when to become pregnant is often a profoundly important decision for…
Abstract Number: 2002 • ACR Convergence 2022
Do SMS and Email Reminders Increase the Rate of Seasonal Influenza Vaccination in RA Patients Treated with Biologics: A Nested Randomized Controlled Trial Within the ART Registry?
Raphaèle Seror¹, Gabriel Baron², Sylvie Miconnet³, Rakiba Belkhir³, Martin Soubrier⁴, pascale thevenot⁵, andre basch⁶, Marie Truchetet⁷, Pascal Claudepierre⁸, Emmanuelle Dernis⁹, Hubert Marotte¹⁰, René-Marc Flipo¹¹, Olivier Brocq¹², Jacques Morel¹³, CARINE SALLIOT¹⁴, Bruno Fautrel¹⁵, Alain Saraux¹⁶, CHARLES LESKE¹⁷, Naïma Hamamouche¹⁸, Thierry schaeverbeke¹⁹, Xavier Mariette²⁰, Adeline Ruyssen-Witrand²¹ and Philippe Ravaud²², ¹University Hospital Paris-Saclay, Le Kremlin Bicêtre, France, ²AP-HP Hôtel Dieu Hospital, Université Paris Descartes, Paris, France, ³Rheumatology departement, Bicêtre, Paris-Saclay university, Le Kremlin Bicêtre, France, ⁴Gabriel-Montpied Hospital, Clermont-Ferrand, France, ⁵French Society of rheumatology, Paris, France, ⁶Infirmerie Protestante de Lyon, Caluire-et-Cuire, France, ⁷Bordeaux University Hospital, Bordeaux, France, ⁸Paris Est Creteil University, Creteil, France, ⁹LE MANS general hospital, LE MANS, France, ¹⁰INSERM 1059, Saint-Etienne, France, ¹¹CHU Lille, Boulogne-Billancourt, France, ¹²Rheumatology- CH Princesse Grace, Monaco, Monaco, ¹³University and CHU Montpellier, Montpellier, France, ¹⁴CHR orleans, Orleans, France, ¹⁵Sorbonne University Paris, France and Pierre Louis Institute of Epidemiology and Public Health, Paris, France, Paris, France, ¹⁶CHU Brest, Brest, France, ¹⁷Hospital, Cholet, France, ¹⁸e-health Services Sanoïa, Gémenos, France, ¹⁹CHU de Bordeaux, Bordeaux, France, ²⁰Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ²¹CHU de Toulouse, Toulouse, France, ²²Université Paris Cité, Hôtel-Dieu, Paris, France
Background/Purpose: In patients treated with biologics, vaccination against influenza is recommended. However, vaccination coverage remains very low. The use of automatic digital reminders is an…
Abstract Number: 0084 • ACR Convergence 2022
Facilitators and Barriers of Vaccine Uptake in Patients with Chronic Inflammatory Rheumatic Disease: A Scoping Review
Silke Neusser¹, Anja Neumann¹, Christian Speckemeier¹, Pauline zur NIeden¹, Sarah Schlierenkamp¹, Anke Walendzik¹, Ute Karbach², Ioana Andreica³, Kristina Vaupel⁴, Xenofon Baraliakos⁵ and Uta Kiltz⁴, ¹Essener Forschungsinstitut für Medizinmanagement, Essen, Germany, ²Institute of Medical Sociology, Health Services Research and Rehabilitation Science (IMVR), Cologne, Germany, ³Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: Patients with chronic inflammatory rheumatic diseases (CIRD) remain underrepresented in receiving vaccinations despite being disproportionately affected by infectious complications. The aim of our study…
Abstract Number: 1065 • ACR Convergence 2022
Biosamples from VEDOSS Patients Show Pathological Signs of SSc: Opportunity for a Biololgical Diagnosis of Disease
Rebecca Ross¹, Emily Clarke¹, Will Merchant¹, Panji Mulipa¹, Natalia Riobo-DelGaldo¹ and Francesco Del Galdo², ¹University of Leeds, Leeds, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health and NIHR Biomedical Research Centre, University of Leeds, Leeds, United Kingdom
Background/Purpose: The VEDOSS study has recently indicated that more than 50% of patients affected by Raynaud’s phenomenon (RP) and specific SSc anti-nuclear antibodies (ANA) and/or…
Abstract Number: 2052 • ACR Convergence 2022
Vaccine Uptake in Women with Systemic Lupus Erythematosus (SLE) in a Large Urban Teaching Hospital Serving a High-Risk Population
J. Patricia Dhar¹, Forsythe Hannah², Louis Saravolatz³ and Susanna Szpunar⁴, ¹Ascension St. John Hospital and Wayne State University School of Medicine, Bloomfield Hills, MI, ²Michigan Department of Human and Health Services, Lansing, MI, ³Ascension St John Hospital and Medical Center, Wayne State University School of Medicine (affiliate), Grosse Pointe Woods, MI, ⁴Ascension St. John Hospital, Grosse Pointe Woods, MI
Background/Purpose: Infections are a major cause of morbidity & mortality in patients with systemic lupus erythematosus (SLE), including vaccine-preventable infections. SLE patients are considered to…
Abstract Number: 0114 • ACR Convergence 2021
The Safety Profile of SARS-CoV-2 Vaccines Among Patients with Immune-Mediated Rheumatic Diseases
Jose A Gomez-Puerta¹, Núria Sapena², Juan C Sarmiento-Monroy³, Ana Belén Azuaga¹, Virginia Ruiz-Esquide², Beatriz Frade-Sosa², Marta Bassas², Rosa Morlà², Andrés Ponce², Juan D Cañete¹, Julio Ramirez², Anna Villella⁴, Antoni Trilla⁴ and Raimon Sanmarti⁵, ¹Rheumatology Department, Hospital Clinic, Barcelona, Spain, ²Rheumatology Department, Hospital Clínic, Barcelona, Spain, ³Hospital Clinic Barcelona, Barcelona, Spain, ⁴Department of Preventive Medicine and Epidemiology, Hospital Clínic, Barcelona, Spain, ⁵Hospital Clínic de Barcelona, Barcelona, Spain
Background/Purpose: The best strategy for the prevention of SARS-CoV-2 infection is vaccination. Both mRNA and vector vaccines have demonstrated a satisfactory safety profile in general…
Abstract Number: 0116 • ACR Convergence 2021
COVID-19 mRNA Vaccine Side Effects Among Individuals with Rheumatic Disease
Kaleb Michaud¹, Adam Cornish², Alison Freifeld¹, Patricia Katz³ and Kristin Wipfler², ¹University of Nebraska Medical Center, Omaha, NE, ²FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ³University of California San Francisco, San Francisco, CA
Background/Purpose: Over 135 million Americans were fully vaccinated to COVID-19 by June 2021, yet there was a paucity of data on side effects for those…
Abstract Number: 0141 • ACR Convergence 2021
Who Gets Influenza Vaccinations Prior to and After a Diagnosis of RA? Results from the Canadian Early Arthritis Cohort (CATCH)
Viviane Ta¹, Orit Schieir², Marie-France Valois¹, Ines Colmegna³, Carol Hitchon⁴, Louis Bessette⁵, Glen Hazlewood⁶, Carter Thorne⁷, Janet Pope⁸, Gilles Boire⁹, Diane Tin¹⁰, Edward Keystone¹¹, Vivian Bykerk¹², Susan Bartlett¹ and CATCH Investigators¹³, ¹McGill University, Montréal, QC, Canada, ²Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, ³The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁴University of Manitoba, Winnipeg, MB, Canada, ⁵Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸University of Western Ontario, London, ON, Canada, ⁹Universite de Sherbrooke, Sherbrooke, QC, Canada, ¹⁰The Arthritis Program Research Group, Newmarket, ON, Canada, ¹¹Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ¹²Hospital for Special Surgery, New York, NY, ¹³Canadian Early Arthritis Cohort Investigators, Toronto, ON, Canada
Background/Purpose: Annual influenza vaccination is recommended for adults with RA, but remains low in established RA. We examined influenza vaccination coverage in the year prior…
Abstract Number: 0461 • ACR Convergence 2021
Plasmablast-derived Autoantibodies from Individuals At-risk for RA That Target RA-relevant Antigens Are Polyreactive with Arthritogenic Bacteria
Meagan Chriswell¹, Jennifer Seifert², Michelle Bloom³, Cliff Rims⁴, Marie Feser⁵, Kevin Deane⁶, Jill Norris⁷, Eddie James⁸, Jane Buckner⁹, William Robinson¹⁰, V. Michael Holers¹¹ and Kristine Kuhn¹², ¹UC Denver SOM, Denver, CO, ²University of Colorado School of Medicine, Littleton, CO, ³Stanford University, Redwood City, CA, ⁴Benaroya Research Institute, Seattle, WA, ⁵University of Colorado Denver, Aurora, CO, ⁶University of Colorado Denver, Denver, CO, ⁷Colorado School of Public Health, Aurora, CO, ⁸Benaroya Research Institute at Virginia Mason, Monroe, WA, ⁹Benaroya Research Institute at Virginia Mason, Seattle, WA, ¹⁰Stanford University, Palo Alto, CA, ¹¹University of Colorado, Denver, CO, ¹²University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: Circulating autoantibodies like ACPA frequently develop years before symptoms of RA, during which the individual is at-risk for disease. Several lines of evidence suggest…

« Previous Page
1
…
8
9
10
11
12
…
15
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].